ArticleHealthcare (Basel, Switzerland)2025
Advanced Computational Modeling and Machine Learning for Risk Stratification, Treatment Optimization, and Prognostic Forecasting in Appendiceal Neoplasms.
Article in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When 'Mucocele' Isn't Just a Mucocele: Diagnostic Pathways and Surgical Management of Appendiceal Mucinous Lesions in a 10-Year Cohort.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAppendiceal neoplasms account for less than 1% of gastrointestinal cancers but are increasing in incidence worldwide. Their marked histological variations and differences create multiple challenges for prognosis and management planning, as current staging systems are limited in certain aspects for capturing the entire disease complexity.
methodsWe synthesized data from 18 large observational studies, including 67,001 patients diagnosed between 1973 and 2024. Using advanced computational modeling, we combined multiple statistical methods and machine learning techniques to improve risk stratification, survival prediction, treatment optimization, and forecasting. A novel overlap-aware weighting methodology was applied to prevent double-counting across overlapping registries.
resultsOur multi-dimensional risk model outperformed TNM staging (C-index 0.758 vs. 0.689), identifying five prognostic groups with five-year overall survival ranging from 88.7% (low-risk neuroendocrine tumors (NETs)) to 27.3% (high-risk signet-ring cell carcinomas (SRCC)). Hierarchical survival analysis demonstrated marked variation across histological variants, with goblet cell adenocarcinoma showing the most favorable outcomes. Causal inference confirmed the survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in stage IV disease (five-year overall survival (OS) 87.4%) and highlighted disparities in outcomes by race and institutional volume. Time-series forecasting projected a 25% to 50% increase in incidence by 2030, highlighting the growing risk of global burden.
conclusionsBy integrating multi-database evidence with advanced modeling and statistical methodologies, our findings demonstrate valuable insights and implications for individualized prognosis, better management decision-making, and health system planning. Our proposed approach and demonstrated methodologies are warranting better progression and advancements in precision oncology and utilization of computational modeling techniques in big data as well as digital health progression landscape.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.